The novel cardiac sarcomere modulator from Edgewise Therapeutics saw substantial improvements in both nonobstructive and obstructive HCM after 12 weeks.
News|Videos|March 20, 2026
ACC.26 Late-Breakers to Watch, With Deepak Bhatt, MD, MPH, MBA
Author(s)Deepak Bhatt, MD, MPH, MBA
Fact checked by: Patrick Campbell
Deepak Bhatt, MD, MPH, MBA, discusses 4 trials to watch at the upcoming ACC.26.
Advertisement
Advertisement
As the cardiovascular community prepares to convene in New Orleans for the
Related to this article
In this Q&A, Leon Kircik, MD, discusses challenging watch-and-wait for molluscum contagiosum with berdazimer gel, 10.3%, at LEADderm 2026.
Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.
Arrowhead's ARO-DIMER-PA cut PCSK9 by 72% and APOC3 by 88% with single doses, driving LDL-C and triglyceride reductions in mixed hyperlipidemia.
Wechsler, of National Jewish Health discusses how oral STAT6 degraders like KT-621 could offer a mechanistically distinct treatment option.
Adam Friedman, MD, breaks down how to say no strategically in dermatology, from delaying an answer to sharing the decision with the requester.
Stay updated with the latest healthcare breakthroughs, including a new ablation catheter for AFib and progress in the hereditary angioedema pipeline.
Kristina Duffin, MD, dean of the Spencer Fox Eccles School of Medicine, discusses leadership, delegation, and coaching at LEADderm 2026.
Advertisement
Advertisement